Novel Monoclonal Antibodies to Treat Hypervirulent Infections

mABs elicit protective immune response in murine infection models resulting in increased bacterial clearance and mice survival Background: Hypervirulent K.pneumonia (hvKp) strains are a major threat worldwide with predominant occurrence in Asia. hvKp?s ability to cause life- threatening infections in healthy individuals, coupled with their ability to acquire MDR phenotype has resulted in an urgent need to develop novel treatment strategy. Such a treatment strategy would ideally be a) not susceptible to resistance development and, b) specific to pathogenic organism without affecting microbiome. Technology Overview: Dr. Fries and her team at Stony Brook University have developed an antibody based approach overcoming the problems associated with the use of antibiotics. The monoclonal antibodies (mABs) generated against a conserved capsular polysaccharidewas demonstrated to confer significant protection and applicability as a diagnostic tool in murine hvKp infection models. Advantages: Highly specific to pathogen l Leaves microbiome unaltered l Less likely to promote drug resistance l Long serum half life of mABs results in reduced dosing frequency l Applicability as a diagnostic tool for early detection of hvKp infection Applications: Infectious diseases l Therapeutics l Diagnostics Intellectual Property Summary: PCT application covering composition and method of use filed (PCT/US16/58257) Stage of Development: Animal model data is available. Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: Further reading: Diago-Navarro E et al., Clin Vaccine Immunol, 24:e00456-16, 2016 Antibodies l hypervirulent Klebsiella pneumoniane , ,
Patent Information:
Technology/Start-up ID: